Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes
Saved in:
Main Authors: | Liliana Italia De Rosa, Martina Catania, Kristiana Kola, Michele Paolisi, Pierpaolo Bianca, Paolo Manunta, Giuseppe Vezzoli, Maria Teresa Sciarrone Alibrandi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-08-01
|
Series: | Kidney International Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024925003444 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Response to the Letter to the Editor Entitled “Refining Tolvaptan Dosing in ADPKD: The Role of Urinary Biomarkers in Enhancing Outcomes”
by: Neera K. Dahl, et al.
Published: (2025-08-01) -
Empowering women at the heart of autosomal dominant polycystic kidney disease: Addressing unique challenges gender-sensitive approach
by: Micaela Petrone, et al.
Published: (2025-07-01) -
Erratum to “Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1063-1075]
by: Kiyotaka Uchiyama, et al.
Published: (2025-07-01) -
Dietary and lifestyle interventions in ADPKD – a review of current literature
by: Martyna Skweres, et al.
Published: (2025-07-01) -
Characterizing the ADPKD-IFT140 Phenotypic Signature With Deep Learning and Advanced Imaging Biomarkers
by: Ahmad Ghanem, et al.
Published: (2025-08-01)